Gastrointestinal neuroendocrine tumors;Neuroendokrine tumoren des gastrointestinaltraktes

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 28-29, 2008, Pages 1505-1510

  Bornschein, J ^a   Kidd, M ^b   Malfertheiner, P ^a   Modlin, Irvin M ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ablation treatment; Carcinoids; Neuroendocrine tumors; Receptor targeted radiopeptide treatment; Somatostatin analogs; Somatostatin receptor scintigraphy

Indexed keywords

ANGIOPEPTIN; ANTIHISTAMINIC AGENT; COLESTYRAMINE; CYPROHEPTADINE; CYTOTOXIC AGENT; DACARBAZINE; DIPHENOXYLATE; DIURETIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; INOTROPIC AGENT; INTERFERON; LOPERAMIDE; OCTREOTIDE; PASIREOTIDE; PENTETREOTIDE; PLATINUM DERIVATIVE; SALBUTAMOL; SOMATOSTATIN DERIVATIVE; STEROID; STREPTOZOCIN; THEOPHYLLINE;

BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL TUMOR; HEART MUSCLE FIBROSIS; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIOFREQUENCY ABLATION; REVIEW; SCREENING TEST; TUMOR LOCALIZATION; DIGESTIVE SYSTEM TUMOR; PATHOPHYSIOLOGY; PROGNOSIS;

DIGESTIVE SYSTEM NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PROGNOSIS;

EID: 47049098155     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1081099     Document Type: Review

References (36)

1. Ahlman H, Nilsson O, Olausson M. Interventional treatment of the carcinoid syndrome. Neuroendocrinology 2004; 80 Suppl 1: 67-73
2. Arnold R, Rinke A, Schmidt C et al. Endocrine tumours of the gastrointestinal tract: Chemotherapy. Best Pract Res Clin Gastroenterol 2005; 19: 649-656
3. Berber E, Flesher N, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002; 26: 985-990
4. Berge T, Lundberg S. Cancer in Malmo 1958-1969. An autopsy study. Acta Pathol Microbiol Scand Suppl 1977; 260: 1-235
5. Bruns C, Lewis I, Briner U et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146: 707-716
6. Buchmann I, Henze M, Engelbrecht S et al. Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617-1626
7. Chung MH, Pisegna J, Spirt M et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001; 130: 954-962
8. Correale P, Sciandivasci A, Intrivici C et al. Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation. Br J Cancer 2007; 7,96: 1343-1347
9. Esser JP, Krenning EP, Teunissen JJ et al. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006; 33: 1346-1351
10. Feldman JM, Lee EM. Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr 1985; 42: 639-643
11. Forrer F, Uusijarvi H, Storch D et al. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005; 46: 1310-1316
12. Frilling A, Weber F, Saner F et al. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery 2006; 140: 968-976
13. Gabriel M, Decristoforo C, Kendler D et al. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518
14. Gay G, Delvaux M, Rey JF. The role of video capsule endoscopy in the diagnosis of digestive diseases: a review of current possibilities. Endoscopy 2004; 36: 913-920
15. Gustafsson BI, Tommeras K, Nordrum I et al. Long-term serotonin administration induces heart valve disease in rats. Circulation 2005; 29,111: 1517-1522
16. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25: 458-511
17. Lewis BS, Eisen GM, Friedman S. A pooled analysis to evaluate results of capsule endoscopy trials. Endoscopy 2005; 37: 960-965
18. Modlin IM, Kidd M, Latich I et al. Current status of gastrointestinal carcinoids. Gastroenterology 2005; 128: 1717-1751
19. Modlin IM, Latich I, Kidd M et al. Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006; 4: 526-547
20. Modlin IM, Latich I, Zikusoka M et al. Gastrointestinal carcinoids: the evolution of diagnostic strategies. J Clin Gastroenterol 2006; 40: 572-582
21. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 15,97: 934-959
22. Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997; 112: 583-590
23. Nilsson O, Kolby L, Wangberg B et al. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 1998; 77: 632-637
24. Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004; 15: 966-973
25. Okamoto Y, Fujii M, Tateiwa S et al. Treatment of multiple rectal carcinoids by endoscopic mucosal resection using a device for esophageal variceal ligation. Endoscopy 2004; 36: 469-470
26. Osborne DA, Zervos EE, Strosberg J et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13: 572-581
27. Plockinger U, Rindi G, Arnold R et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004; 80: 394-424
28. Rindi G, Kloppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 395-401
29. Sarmiento JM, Heywood G, Rubin J et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197: 29-37
30. Schmid HA. Pasireotide (SOM230): Development, mechanism of action and potential applications. Mol Cell Endocrinol 2008; 286: 69-74
31. Solcia E, Kloppel G, Sabin LH et al. Histological typing of endocrine tumours. WHO international histological classification of tumours. Berlin: Springer, 2000
32. Sutcliffe R, Maguire D, Ramage J et al. Management of neuroendocrine liver metastases. Am J Surg 2004; 187: 39-46
33. Tormey WP, FitzGerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J 1995; 71: 542-545
34. Vilar E, Salazar R, Perez-Garcia J et al. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007; 14: 221-232
35. Welsh JS, Kennedy AS, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 62-73
36. Zuetenhorst JM, Taal BG. Metastatic carcinoid tumors: a clinical review. Oncologist 2005; 10: 123-131